主要文件

查看所有文档

SML4257

Chidamide

Name: Chidamide
Brand: SIGMA

≥98% (HPLC), powder, histone deacetylase (HDAC) inhibitor

别名:

CS 055, CS-055, CS055, HBI 8000, HBI-8000, HBI8000, Tucidinostat, N-(2-Amino-4-fluorophenyl)-4-[[[(2E)-1-oxo-3-(3-pyridinyl)-2-propen-1-yl]amino]methyl]benzamide

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₂H₁₉FN₄O₂

化学文摘社编号:

1616493-44-7

分子量:

390.41

MDL number:

MFCD28100259

NACRES:

NA.21

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Application

Chidamide may be used as an enhancer of zeste homolog 2 (EZH2) inhibitor and study the antileukemia effects in vivo in leukemia-bearing nude mouse models

Biochem/physiol Actions

Chidamide (CS055, HBI-8000, Tucidinostat) is an orally available benzamide that inhibits against class I histone deaceylases HDAC1/2/3/8 (IC50 of 95/160/67/733 nM), class II2b HDAC10 (IC50 = 78 nM), and class IV HDAC11 (IC50 = 432 nM), but not class IIa HDAC4/5/7/9 or IIb HDAC10 (IC50 >30 μM). Chidamide effectively upregulates cellular acetylation levels of histone H3 and H4 (3 μM for 24 h in SKM-1 and HEL cultures) and exhibits anti-cancer efficacy both in cultures and in vivo.

pictograms

GHS07

signalword

Warning

hcodes

H302

pcodes

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Induction of apoptosis by HBI-8000 in adult T-cell leukemia/lymphoma is associated with activation of Bim and NLRP3.

Hiroo Hasegawa et al.

Cancer science, 107(8), 1124-1133 (2016-05-20)

Adult T-cell leukemia/lymphoma (ATL) is an aggressive T-cell malignancy caused by human T-cell lymphotropic virus 1. Treatment options for acute ATL patients include chemotherapy, stem cell transplantation, and recently the anti-chemokine (C-C motif) receptor 4 antibody, although most patients still

CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells.

Ke Gong et al.

The Biochemical journal, 443(3), 735-746 (2012-02-22)

CS055 (Chidamide/HBI-8000) is a novel benzamide-type HDACi (histone deacetylase inhibitor), which has entered Phase I clinical trials in the U.S. and Phase II/III in China. In the present study, we investigated the effects of CS055 on proliferation, differentiation and apoptosis

Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.

Zhi-Qiang Ning et al.

Cancer chemotherapy and pharmacology, 69(4), 901-909 (2011-11-15)

Chidamide (CS055/HBI-8000) is a new histone deacetylase (HDAC) inhibitor of the benzamide class currently under clinical development in cancer indications. This study reports the in vitro and in vivo antitumor characteristics of the compound. Selectivity and potency of chidamide in

全球贸易项目编号

货号	GTIN
SML4257-10MG	04065273262568
SML4257-50MG	04065273262575

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持